Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin

Pierre P. Major, Ram P. Agarwal, Donald W. Kufe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have administered five courses of arabinofuranosyladenine (ara-A) and deoxycoformycin (DCF) to two patients and have studied the effects of DCF on the pharmacokinetics of ara-A. Ara-A was given by IV infusion over 3 h at a dose of 300 mg/m2/day for 3 days on the first two courses of treatment for each patient. One patient received a third course at a dose of 300 mg/m2/day every 12 h for 3 days. During the first course of treatment, patients received DCF (10 mg/m2) 60 min prior to the ara-A infusion on days 2 and 3 only. However, during subsequent courses, DCF was administered on each of the 3 days. On day 1 of the first course of treatment ara-A was not detectable in the plasma, while ara-hypoxanthine (ara-hyp) reached levels of up to 12.0 μg/ml. On day 2, DCF pretreatment resulted in detectable ara-A levels and decreased ara-hyp. On day 3, the levels of ara-A increased further and ara-hyp was no longer detectable. On subsequent courses, the administration of DCF on each of the 3 days of treatment resulted in detectable ara-A levels on day 1, with progressive increases on days 2 and 3. During the second course of treatment, increases in the excretion half-life of ara-A were noted during the 3-day treatment schedule, with values increasing from 258.2 min to 546 min and from 77.3 min to 219 min for patients I and II, respectively. Peak CSF ara-A levels were approximately one-third of peak plasma levels. No toxicity was encountered in patients treated at these doses of ara-A and DCF. Abrupt declines in peripheral blast counts were observed in each patient.

Original languageEnglish
Pages (from-to)125-128
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume10
Issue number2
DOIs
StatePublished - Feb 1 1983
Externally publishedYes

Fingerprint

Pentostatin
Vidarabine
Clinical Pharmacology
Hypoxanthine
Therapeutics
Patient treatment
Plasmas
Pharmacokinetics
Half-Life
Toxicity
Appointments and Schedules

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin. / Major, Pierre P.; Agarwal, Ram P.; Kufe, Donald W.

In: Cancer Chemotherapy and Pharmacology, Vol. 10, No. 2, 01.02.1983, p. 125-128.

Research output: Contribution to journalArticle

Major, Pierre P. ; Agarwal, Ram P. ; Kufe, Donald W. / Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin. In: Cancer Chemotherapy and Pharmacology. 1983 ; Vol. 10, No. 2. pp. 125-128.
@article{73ea4f254deb4ba58f6a414f02610f57,
title = "Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin",
abstract = "We have administered five courses of arabinofuranosyladenine (ara-A) and deoxycoformycin (DCF) to two patients and have studied the effects of DCF on the pharmacokinetics of ara-A. Ara-A was given by IV infusion over 3 h at a dose of 300 mg/m2/day for 3 days on the first two courses of treatment for each patient. One patient received a third course at a dose of 300 mg/m2/day every 12 h for 3 days. During the first course of treatment, patients received DCF (10 mg/m2) 60 min prior to the ara-A infusion on days 2 and 3 only. However, during subsequent courses, DCF was administered on each of the 3 days. On day 1 of the first course of treatment ara-A was not detectable in the plasma, while ara-hypoxanthine (ara-hyp) reached levels of up to 12.0 μg/ml. On day 2, DCF pretreatment resulted in detectable ara-A levels and decreased ara-hyp. On day 3, the levels of ara-A increased further and ara-hyp was no longer detectable. On subsequent courses, the administration of DCF on each of the 3 days of treatment resulted in detectable ara-A levels on day 1, with progressive increases on days 2 and 3. During the second course of treatment, increases in the excretion half-life of ara-A were noted during the 3-day treatment schedule, with values increasing from 258.2 min to 546 min and from 77.3 min to 219 min for patients I and II, respectively. Peak CSF ara-A levels were approximately one-third of peak plasma levels. No toxicity was encountered in patients treated at these doses of ara-A and DCF. Abrupt declines in peripheral blast counts were observed in each patient.",
author = "Major, {Pierre P.} and Agarwal, {Ram P.} and Kufe, {Donald W.}",
year = "1983",
month = "2",
day = "1",
doi = "10.1007/BF00446224",
language = "English",
volume = "10",
pages = "125--128",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin

AU - Major, Pierre P.

AU - Agarwal, Ram P.

AU - Kufe, Donald W.

PY - 1983/2/1

Y1 - 1983/2/1

N2 - We have administered five courses of arabinofuranosyladenine (ara-A) and deoxycoformycin (DCF) to two patients and have studied the effects of DCF on the pharmacokinetics of ara-A. Ara-A was given by IV infusion over 3 h at a dose of 300 mg/m2/day for 3 days on the first two courses of treatment for each patient. One patient received a third course at a dose of 300 mg/m2/day every 12 h for 3 days. During the first course of treatment, patients received DCF (10 mg/m2) 60 min prior to the ara-A infusion on days 2 and 3 only. However, during subsequent courses, DCF was administered on each of the 3 days. On day 1 of the first course of treatment ara-A was not detectable in the plasma, while ara-hypoxanthine (ara-hyp) reached levels of up to 12.0 μg/ml. On day 2, DCF pretreatment resulted in detectable ara-A levels and decreased ara-hyp. On day 3, the levels of ara-A increased further and ara-hyp was no longer detectable. On subsequent courses, the administration of DCF on each of the 3 days of treatment resulted in detectable ara-A levels on day 1, with progressive increases on days 2 and 3. During the second course of treatment, increases in the excretion half-life of ara-A were noted during the 3-day treatment schedule, with values increasing from 258.2 min to 546 min and from 77.3 min to 219 min for patients I and II, respectively. Peak CSF ara-A levels were approximately one-third of peak plasma levels. No toxicity was encountered in patients treated at these doses of ara-A and DCF. Abrupt declines in peripheral blast counts were observed in each patient.

AB - We have administered five courses of arabinofuranosyladenine (ara-A) and deoxycoformycin (DCF) to two patients and have studied the effects of DCF on the pharmacokinetics of ara-A. Ara-A was given by IV infusion over 3 h at a dose of 300 mg/m2/day for 3 days on the first two courses of treatment for each patient. One patient received a third course at a dose of 300 mg/m2/day every 12 h for 3 days. During the first course of treatment, patients received DCF (10 mg/m2) 60 min prior to the ara-A infusion on days 2 and 3 only. However, during subsequent courses, DCF was administered on each of the 3 days. On day 1 of the first course of treatment ara-A was not detectable in the plasma, while ara-hypoxanthine (ara-hyp) reached levels of up to 12.0 μg/ml. On day 2, DCF pretreatment resulted in detectable ara-A levels and decreased ara-hyp. On day 3, the levels of ara-A increased further and ara-hyp was no longer detectable. On subsequent courses, the administration of DCF on each of the 3 days of treatment resulted in detectable ara-A levels on day 1, with progressive increases on days 2 and 3. During the second course of treatment, increases in the excretion half-life of ara-A were noted during the 3-day treatment schedule, with values increasing from 258.2 min to 546 min and from 77.3 min to 219 min for patients I and II, respectively. Peak CSF ara-A levels were approximately one-third of peak plasma levels. No toxicity was encountered in patients treated at these doses of ara-A and DCF. Abrupt declines in peripheral blast counts were observed in each patient.

UR - http://www.scopus.com/inward/record.url?scp=0020574580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020574580&partnerID=8YFLogxK

U2 - 10.1007/BF00446224

DO - 10.1007/BF00446224

M3 - Article

VL - 10

SP - 125

EP - 128

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -